Sabet Samie, Condren Michelle E, Boston Angela F, Doak Lauren C, Chalmers Laura J
J Pediatr Pharmacol Ther. 2018 Sep-Oct;23(5):351-361. doi: 10.5863/1551-6776-23.5.351.
Despite pharmacotherapeutic advancements in the management of type 1 diabetes mellitus during the past several decades, patients struggle to achieve glycemic goals. Additionally, hypoglycemia, especially in extremes of age, decreases quality of life. The lack of optimal glycemic control and risk for hypoglycemia are multifactorial. Nevertheless, endeavors aiming to develop pharmacotherapeutic options with enhanced pharmacokinetic, pharmacodynamic, and clinical profiles continue. This review article discusses recent ventures in 3 categories of insulin, non-insulin, and glucagon products.
尽管在过去几十年中1型糖尿病的药物治疗取得了进展，但患者仍难以实现血糖目标。此外，低血糖，尤其是在年龄极端情况下，会降低生活质量。血糖控制不佳和低血糖风险是多因素的。然而，开发具有更好药代动力学、药效学和临床特征的药物治疗选择的努力仍在继续。这篇综述文章讨论了胰岛素、非胰岛素和胰高血糖素产品三类药物的最新进展。
